Expert Perspectives

Leading oncologists and researchers provide their insights on the emerging field of metabo-oncology, including the latest clinical developments and the current understandings in research.

Hope S. Rugo, M.D.

Medical Oncologist & Hematologist, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

Let’s say you have a patient who is over the target BMI. It would be great if you could say, “Here’s a medication you can take to address that, and here’s an exercise program that comes with it, and it has an app. We believe this will improve your response to therapy and your chance of survival, or at least your well-being.” That would be enormously appealing.

Kathryn H. Schmitz, Ph.D., MPH

Associate Director of Population Sciences, Penn State University

When we published recommendations on exercise oncology in 2010, we were trying to put the oncology world on notice that “rest, take it easy, don’t push yourself” is dead. Doctors need to be prescribing exercise for their patients during and after their treatment.

Neil M. Iyengar, M.D.

Medical Oncologist, Memorial Sloan Kettering Cancer Center

While the tumor-centric approach — where cancer prevention and cancer treatments are directed at the biology of the tumor itself — has been successful, we’re learning we can enhance this success by also focusing on the person as a whole and on what’s going on around the tumor. This is where metabo-oncology really becomes important, because the metabolic state of a person as a whole contributes quite a bit to how tumors develop and behave.

Andrew J. Dannenberg, M.D.

Professor of Medicine, Weill Cornell Medical College

This is a global issue we’re dealing with. The epidemic of obesity, of excess adiposity, is here to stay. Therefore, finding strategies to alter tumor growth in those with excess adiposity is very important.